50% af de patienter, der blev behandlet med anagrelid, over 60 år, og der var ikke behov for nogen aldersspecifikke ændringer i dosis for disse patienter.
During clinical development approximately 50% of the patients treated with anagrelide were over 60 years of age and no age specific alterations in dosage were required in these patients.